Research programme: anti-fungals - MycoLogicsAlternative Names: Anti-fungals research programme - MycoLogics
Latest Information Update: 13 Jan 2003
At a glance
- Originator MycoLogics; Nonindustrial source
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Mycoses
Most Recent Events
- 13 Jan 2003 No development reported - Preclinical for Mycoses in USA (unspecified route)
- 10 Oct 2000 Preclinical development for Mycoses in USA (Unknown route)